ANNX
- Annexon, Inc.
()
Overview
Company Summary
Annexon, Inc. is a biopharmaceutical company dedicated to developing innovative therapies for patients suffering from autoimmune and neurodegenerative disorders. Their primary focus is on modulating the immune system to address these conditions.
ANNX employs a unique approach by targeting the complement pathway, a component of our immune system that plays a crucial role in disease pathogenesis. By designing precise therapies that selectively inhibit or activate specific components of the complement system, Annexon aims to restore immune homeostasis and halt the progression of various diseases.
The company's pipeline includes investigational drugs at different stages of development. Their lead product candidate, ANX005, is a monoclonal antibody designed to target C1q, a component of the complement system. ANX005 aims to reduce complement activity and treat several autoimmune diseases, including Guillain-Barr� Syndrome and Amyotrophic Lateral Sclerosis.
Another promising candidate is ANX007, which targets C1q and C3b, two complement components involved in neurodegenerative disorders. Annexon believes ANX007 has potential applications in treating diseases such as Alzheimer's disease and Huntington's disease.
ANNX leverages deep scientific expertise and collaborations with leading research institutions to drive innovation in their product development. They aim to improve patient outcomes and provide much-needed therapeutic options for those affected by autoimmune and neurodegenerative disorders.